Literature DB >> 18997299

Administration and scoring variance on the ADAS-Cog.

Donald J Connor1, Marwan N Sabbagh.   

Abstract

The Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) is the most commonly used primary outcome instrument in clinical trials for treatments of dementia. Variations in forms, administration procedures and scoring rules, along with rater turnover and intra-rater drift may decrease the reliability of the instrument. A survey of possible variations in the ADAS-Cog was administered to 26 volunteer raters at a clinical trials meeting. Results indicate notable protocol variations in the forms used, administration procedures, and scoring rules. Since change over time is used to determine treatment effect in clinical trials, standardizing the instrument's ambiguities and addressing common problems will greatly increase the instrument's reliability and thereby enhance its sensitivity to treatment effects.

Entities:  

Mesh:

Year:  2008        PMID: 18997299      PMCID: PMC2727511          DOI: 10.3233/jad-2008-15312

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  4 in total

1.  Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

Authors:  R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

2.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

Authors:  K L Davis; L J Thal; E R Gamzu; C S Davis; R F Woolson; S I Gracon; D A Drachman; L S Schneider; P J Whitehouse; T M Hoover
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

3.  Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID).

Authors:  Frans R Verhey; Peter Houx; Natascha Van Lang; Felicia Huppert; Gabriella Stoppe; Jos Saerens; Peter Böhm; Luc De Vreese; Arto Nordlund; Peter P DeDeyn; Mirco Neri; Jordi Peña-Casanova; Anders Wallin; Eduard Bollen; Huub Middelkoop; Marie-Christine Nargeot; Michèle Puel; Ulrich M Fleischmann; Jellemer Jolles
Journal:  Int J Geriatr Psychiatry       Date:  2004-01       Impact factor: 3.485

4.  A new rating scale for Alzheimer's disease.

Authors:  W G Rosen; R C Mohs; K L Davis
Journal:  Am J Psychiatry       Date:  1984-11       Impact factor: 18.112

  4 in total
  20 in total

1.  The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.

Authors:  Jeannine Skinner; Janessa O Carvalho; Guy G Potter; April Thames; Elizabeth Zelinski; Paul K Crane; Laura E Gibbons
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

2.  Dementia-Related Neuropsychological Testing Considerations in Non-Hispanic White and Latino/Hispanic Populations.

Authors:  Shanna L Burke; Mitra Naseh; Miriam J Rodriguez; Aaron Burgess; David Loewenstein
Journal:  Psychol Neurosci       Date:  2019-03-11

3.  Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015.

Authors:  Dev Mehta; Robert Jackson; Gaurav Paul; Jiong Shi; Marwan Sabbagh
Journal:  Expert Opin Investig Drugs       Date:  2017-06       Impact factor: 6.206

4.  Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.

Authors:  J Cummings; P Aisen; R Barton; J Bork; R Doody; J Dwyer; J C Egan; H Feldman; D Lappin; L Truyen; S Salloway; R Sperling; G Vradenburg
Journal:  J Prev Alzheimers Dis       Date:  2016-03-04

5.  Study protocol: EXERcise and cognition in sedentary adults with early-ONset dementia (EXERCISE-ON).

Authors:  Astrid M Hooghiemstra; Laura H P Eggermont; Philip Scheltens; Wiesje M van der Flier; Jet Bakker; Mathieu H G de Greef; Peter A Koppe; Erik J A Scherder
Journal:  BMC Neurol       Date:  2012-08-16       Impact factor: 2.474

6.  Globalization of Alzheimer's disease clinical trials.

Authors:  Jeffrey Cummings; Robert Reynders; Kate Zhong
Journal:  Alzheimers Res Ther       Date:  2011-08-17       Impact factor: 6.982

7.  Investigational drugs for the treatment of AD: what can we learn from negative trials?

Authors:  Sandra A Jacobson; Marwan N Sabbagh
Journal:  Alzheimers Res Ther       Date:  2011-04-15       Impact factor: 6.982

8.  Neurostimulation for cognitive enhancement in Alzheimer's disease (the NICE-AD study): a randomized clinical trial.

Authors:  Emma Gulley; Joe Verghese; Helena M Blumen; Emmeline Ayers; Cuiling Wang; Russell K Portenoy; Jessica L Zwerling; Erica Weiss; Helena Knotkova
Journal:  Neurodegener Dis Manag       Date:  2021-07-09

9.  Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia.

Authors:  Yang Gao; Rónán O'Caoimh; Liam Healy; David M Kerins; Joseph Eustace; Gordon Guyatt; David Sammon; D William Molloy
Journal:  BMJ Open       Date:  2013-07-25       Impact factor: 2.692

10.  Genetic variants beyond amyloid and tau associated with cognitive decline: A cohort study.

Authors:  Hang-Rai Kim; Taeyeop Lee; Jung Kyoon Choi; Yong Jeong
Journal:  Neurology       Date:  2020-09-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.